Also known as E2007, ER-155055-90, Fycompa®, E 2007, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, pérampanel, Perampanelum
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
~8 min read
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
Perampanel was approved in 2012, and , its optimal role in the treatment of epilepsy relative to other drugs is not clear. It is the first anti-epileptic drug in the class of selective non-competitive antagonist of AMPA receptors.
via Wikipedia infobox
via PubMed
via Wikidata sitelinks · CC0
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).